This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Maroto P, Villavicencio H, Piñol C, Urruticoechea L.Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain. Value in Health 9: A280, No. 6, Nov-Dec 2006
Rights and permissions
About this article
Cite this article
Sorafenib a cost-effective option in renal cancer. Pharmacoecon. Outcomes News 516, 1 (2006). https://doi.org/10.2165/00151234-200605160-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605160-00001